Rituximab monotherapy for patients with recurrent primary CNS lymphoma.
作者信息
Batchelor T T, Grossman S A, Mikkelsen T, Ye X, Desideri S, Lesser G J
机构信息
Stephen E. and Catherine Pappas Center for Neuro-Oncology, Yawkey 9E, Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA 02114, USA.
出版信息
Neurology. 2011 Mar 8;76(10):929-30. doi: 10.1212/WNL.0b013e31820f2d94.
Abstract
摘要
相似文献
1
Rituximab monotherapy for patients with recurrent primary CNS lymphoma.利妥昔单抗单药治疗复发性原发性中枢神经系统淋巴瘤患者。
Neurology. 2011 Mar 8;76(10):929-30. doi: 10.1212/WNL.0b013e31820f2d94.
2
Primary central nervous system lymphoma treated with rituximab plus temozolomide in a second line schedule.利妥昔单抗联合替莫唑胺二线方案治疗原发性中枢神经系统淋巴瘤
Clin Transl Oncol. 2007 Jul;9(7):465-7. doi: 10.1007/s12094-007-0086-4.
3
Combination therapy with rituximab and temozolomide for recurrent and refractory primary central nervous system lymphoma.利妥昔单抗联合替莫唑胺治疗复发性和难治性原发性中枢神经系统淋巴瘤。
Yonsei Med J. 2011 Nov;52(6):1031-4. doi: 10.3349/ymj.2011.52.6.1031.
4
Is there still a need for specific central nervous system directed prophylaxis for diffuse large B-cell lymphoma in the rituximab era?在利妥昔单抗时代，弥漫性大B细胞淋巴瘤是否仍需要针对中枢神经系统的特异性预防措施？
Leuk Lymphoma. 2014 Mar;55(3):471-3. doi: 10.3109/10428194.2013.830306. Epub 2013 Nov 14.
5
Immuno-chemotherapy with a combination of rituximab, methotrexate, pirarubicin and procarbazine for patients with primary CNS lymphoma--a preliminary report.利妥昔单抗、甲氨蝶呤、吡柔比星和丙卡巴肼联合免疫化疗治疗原发性中枢神经系统淋巴瘤患者——初步报告
Leuk Lymphoma. 2007 May;48(5):1019-22. doi: 10.1080/10428190701248009.
6
High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma.高剂量甲氨蝶呤联合或不联合利妥昔单抗用于新诊断的原发性中枢神经系统淋巴瘤
Neurology. 2015 Feb 17;84(7):758-9. doi: 10.1212/01.wnl.0000461333.55612.f2.
7
Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis.利妥昔单抗对弥漫性大 B 细胞淋巴瘤患者中枢神经系统复发的影响：系统评价和荟萃分析。
Leuk Lymphoma. 2014 Mar;55(3):509-14. doi: 10.3109/10428194.2013.811239. Epub 2013 Jul 29.
8
Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study.利妥昔单抗、甲氨蝶呤、丙卡巴肼、长春新碱及强化阿糖胞苷巩固治疗老年原发性中枢神经系统淋巴瘤（PCNSL）：一项LOC网络研究
J Neurooncol. 2017 Jun;133(2):315-320. doi: 10.1007/s11060-017-2435-7. Epub 2017 Apr 21.
9
Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.中枢神经系统（CNS）复发弥漫性大 B 细胞淋巴瘤（DLBCL）：利妥昔单抗治疗前后。
Ann Hematol. 2011 Jul;90(7):809-18. doi: 10.1007/s00277-010-1150-7. Epub 2011 Jan 13.
10
Successful treatment of AIDS-associated, primary CNS lymphoma with rituximab- and methotrexate-based chemotherapy and autologous stem cell transplantation.采用基于利妥昔单抗和甲氨蝶呤的化疗及自体干细胞移植成功治疗艾滋病相关的原发性中枢神经系统淋巴瘤。
Infection. 2014 Apr;42(2):445-7. doi: 10.1007/s15010-013-0579-8. Epub 2014 Jan 20.
引用本文的文献
1
Prospective phase II trial of first-line rituximab, methotrexate, and orelabrutinib (R-MO) in primary central nervous system lymphoma.利妥昔单抗、甲氨蝶呤和奥雷巴替尼（R-MO）一线治疗原发性中枢神经系统淋巴瘤的前瞻性II期试验。
Blood Cancer J. 2025 Apr 29;15(1):81. doi: 10.1038/s41408-025-01278-w.
2
Optimization and Validation of the Cationization Method for the Fab' Fragment of Antibody Rituximab.利妥昔单抗抗体Fab'片段阳离子化方法的优化与验证
ACS Omega. 2025 Mar 26;10(13):12880-12890. doi: 10.1021/acsomega.4c07727. eCollection 2025 Apr 8.
3
A phase Ib study evaluating the c-MET inhibitor INC280 (capmatinib) in combination with bevacizumab in patients with high-grade glioma.一项Ib期研究，评估c-MET抑制剂INC280（卡马替尼）联合贝伐单抗治疗高级别胶质瘤患者的疗效。
Neurooncol Adv. 2024 Dec 11;7(1):vdae220. doi: 10.1093/noajnl/vdae220. eCollection 2025 Jan-Dec.
4
Molecular Mechanisms and Therapeutic Prospects of Immunotherapy and Targeted Therapy in Primary Central Nervous System Lymphoma.原发性中枢神经系统淋巴瘤免疫治疗和靶向治疗的分子机制及治疗前景
Technol Cancer Res Treat. 2025 Jan-Dec;24:15330338251319394. doi: 10.1177/15330338251319394.
5
Rituximab in the Treatment of Non-Infectious Uveitis: A Review.利妥昔单抗治疗非感染性葡萄膜炎：综述
J Inflamm Res. 2024 Sep 29;17:6765-6780. doi: 10.2147/JIR.S477708. eCollection 2024.
6
A Phase II Study Assessing Long-term Response to Ibrutinib Monotherapy in Recurrent or Refractory CNS Lymphoma.一项评估伊布替尼单药治疗复发性或难治性中枢神经系统淋巴瘤的长期应答的 II 期研究。
Clin Cancer Res. 2024 Sep 13;30(18):4005-4015. doi: 10.1158/1078-0432.CCR-24-0605.
7
HLA dependency and possible clinical relevance of intrathecally synthesized anti-IgLON5 IgG4 in anti-IgLON5 disease.抗 IgLON5 病患者鞘内合成的抗 IgLON5 IgG4 的 HLA 依赖性和可能的临床相关性。
Front Immunol. 2024 May 16;15:1376456. doi: 10.3389/fimmu.2024.1376456. eCollection 2024.
8
Clinical implications of CSF-ctDNA positivity in newly diagnosed diffuse large B cell lymphoma.脑脊液 ctDNA 阳性对初诊弥漫性大 B 细胞淋巴瘤的临床意义。
Leukemia. 2024 Jul;38(7):1541-1552. doi: 10.1038/s41375-024-02279-7. Epub 2024 May 15.
9
Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma.格罗菲他单抗可刺激中枢神经系统肿瘤的免疫细胞浸润，并在继发性中枢神经系统淋巴瘤中诱导临床应答。
Blood. 2024 Jul 25;144(4):457-461. doi: 10.1182/blood.2024024168.
10
Clinical characteristics and outcomes of Epstein-Barr virus viral load after allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植后 EBV 载量的临床特征和结果。
Ann Hematol. 2024 Mar;103(3):935-946. doi: 10.1007/s00277-023-05596-6. Epub 2023 Dec 29.
本文引用的文献
1
First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma.钇-90标记替伊莫单抗（泽瓦林）用于原发性中枢神经系统淋巴瘤的前瞻性试验的首次报告。
Neuro Oncol. 2009 Aug;11(4):423-9. doi: 10.1215/15228517-2008-108. Epub 2008 Dec 5.
2
Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma.联合免疫化疗与减少全脑放疗用于新诊断的原发性中枢神经系统淋巴瘤。
J Clin Oncol. 2007 Oct 20;25(30):4730-5. doi: 10.1200/JCO.2007.12.5062.
3
Imaging of central nervous system lymphomas with iodine-123 labeled rituximab.用碘-123标记的利妥昔单抗对中枢神经系统淋巴瘤进行成像。
Eur J Haematol. 2005 Apr;74(4):348-52. doi: 10.1111/j.1600-0609.2004.00401.x.
4
Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.利妥昔单抗与替莫唑胺联合用于原发性中枢神经系统淋巴瘤的挽救治疗。
Neurology. 2004 Sep 14;63(5):901-3. doi: 10.1212/01.wnl.0000137050.43114.42.
5
Response criteria for phase II studies of supratentorial malignant glioma.幕上恶性胶质瘤II期研究的反应标准。
J Clin Oncol. 1990 Jul;8(7):1277-80. doi: 10.1200/JCO.1990.8.7.1277.
Zotero 插件